This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

CELEBREX
Arthritis/rheumatic disorders
Dysmenorrhea
Nonnarcotic analgesics
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

CELEBREX Rx

Generic Name and Formulations:
Celecoxib 50mg, 100mg, 200mg, 400mg; caps.

Company:
Pfizer Inc.

Therapeutic Use:

Indications for CELEBREX:

Osteoarthritis (OA). Rheumatoid arthritis (RA). Ankylosing spondylitis (AS). Juvenile rheumatoid arthritis (JRA).

Adult:

Use lowest effective dose for shortest duration. ≥18yrs: OA: 200mg once daily or 100mg twice daily. RA: 100–200mg twice daily. AS: 200mg in 1–2 divided doses; if no response after 6 weeks, 400mg once daily may be tried. <50kg: start at lowest recommended dose. Moderate hepatic impairment, CYP2C9 poor metabolizers: reduce dose by 50%.

Children:

<2yrs or <10kg: not studied. Use lowest effective dose for shortest duration. May sprinkle capsule contents into applesauce. See full labeling. JRA: ≥2yrs (≥10kg to ≤25kg): 50mg twice daily; (>25kg): 100mg twice daily. CYP2C9 poor metabolizers: consider alternatives.

Contraindications:

Sulfonamide, aspirin or other NSAID allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver or renal disease develop, or if abnormal liver function tests persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C: <30 weeks gestation); (Cat.D: ≥30 weeks gestation; avoid). Nursing mothers.

Interactions:

Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Caution with CYP2C9 inhibitors (eg, fluconazole), CYP2C9 inducers (eg, rifampin), or drugs that are metabolized by CYP2D6 (eg, atomoxetine).

Pharmacological Class:

NSAID (COX-2 inhibitor).

Adverse Reactions:

Abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper RTI; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypertension, anaphylaxis, anemia; also children: headache, fever, cough.

Generic Availability:

YES

How Supplied:

Caps 100mg, 200mg—100, 500; 50mg, 400mg—60

Indications for CELEBREX:

Dysmenorrhea.

Adult:

Use lowest effective dose for shortest duration. ≥18yrs: 400mg once then 200mg more on 1st day if needed, then 200mg twice daily. <50kg: start at lowest recommended dose. Moderate hepatic impairment, CYP2C9 poor metabolizers: reduce dose by 50%.

Children:

<18yrs: not recommended.

Contraindications:

Sulfonamide, aspirin or other NSAID allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver or renal disease develop, or if abnormal liver function tests persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C: <30 weeks gestation); (Cat.D: ≥30 weeks gestation; avoid). Nursing mothers.

Interactions:

Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Caution with CYP2C9 inhibitors (eg, fluconazole), CYP2C9 inducers (eg, rifampin), or drugs that are metabolized by CYP2D6 (eg, atomoxetine).

Pharmacological Class:

NSAID (COX-2 inhibitor).

Adverse Reactions:

Abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper RTI, rash (may be serious); cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypertension, anaphylaxis, anemia.

Generic Availability:

YES

How Supplied:

Caps 100mg, 200mg—100, 500; 50mg, 400mg—60

Indications for CELEBREX:

Acute pain.

Adult:

Use lowest effective dose for shortest duration. ≥18yrs: 400mg once then 200mg more on 1st day if needed, then 200mg twice daily. <50kg: start at lowest recommended dose. Moderate hepatic impairment, CYP2C9 poor metabolizers: reduce dose by 50%.

Children:

<18yrs: not recommended.

Contraindications:

Sulfonamide, aspirin or other NSAID allergy. Coronary artery bypass graft surgery.

Warnings/Precautions:

Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver or renal disease develop, or if abnormal liver function tests persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C: <30 weeks gestation); (Cat.D: ≥30 weeks gestation; avoid). Nursing mothers.

Interactions:

Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors (eg, captopril), ARBs (eg, losartan), or β-blockers; monitor closely. Potentiates digoxin; monitor levels. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity. Caution with CYP2C9 inhibitors (eg, fluconazole), CYP2C9 inducers (eg, rifampin), or drugs that are metabolized by CYP2D6 (eg, atomoxetine).

Pharmacological Class:

NSAID (COX-2 inhibitor).

Adverse Reactions:

Abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper RTI, rash (may be serious); cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, hypertension, anaphylaxis, anemia.

Generic Availability:

YES

How Supplied:

Caps 100mg, 200mg—100, 500; 50mg, 400mg—60

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Groin swelling - red flag symptomsExternal web site

This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...

0.50 Credits
Red flags

Erectile dysfunction - red flag symptomsExternal web site

This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...

0.50 Credits
Red flags

Headache - red flag symptomsExternal web site

Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Basal cell carcinoma: clinical reviewExternal web site

In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...

1.50 Credits
Clinical Review

Cardiomyopathy: clinical reviewExternal web site

This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...

1.50 Credits
Clinical Review

Parkinson's disease: clinical reviewExternal web site

Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »